Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jan-Feb;69(1):81-85.
doi: 10.4103/ijd.ijd_236_23. Epub 2024 Feb 27.

The Significance of Eosinophil-to-Lymphocyte Ratio in Predicting Response to Omalizumab Treatment in Patients with Bullous Pemphigoid: A Case Series

Gülfem Akin  1 , Ceylan Avci  1 , Sevgi Akarsu  1
Affiliations
Case Reports

The Significance of Eosinophil-to-Lymphocyte Ratio in Predicting Response to Omalizumab Treatment in Patients with Bullous Pemphigoid: A Case Series

Gülfem Akin et al. Indian J Dermatol. 2024 Jan-Feb.

Abstract

Omalizumab, a monoclonal anti-IgE antibody, has been used off-label in a few case series of bullous pemphigoids (BPs) with rapid efficacy and high safety profile. However, there is a lack of data to select patients who would get the most therapeutic benefit from omalizumab therapy. To assess if eosinophil-to-lymphocyte ratio (ELR), total serum IgE level, and serum eosinophil percentage would be useful in predicting response to omalizumab therapy in patients with BP. Medical records of 10 patients with BP treated with omalizumab were retrospectively analysed for clinical and laboratory data. ELRs, total serum IgE levels, and serum eosinophil percentages were compared between groups of complete responders and partial responders/flare-ups, but the results were not statistically significant. Studies with larger sample sizes should be done to predict the role of type 2 immunity markers in omalizumab therapy of BP patients.

Keywords: Bullous pemphigoid; eosinophil; lymphocyte; omalizumab; type 2 immunity.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Ben-Shoshan D, Litvinov IV, Netchiporouk E. The future of bullous pemphigoid (BP): New and promising drugs may revolutionize treatment course for BP patients. J Cutan Med Surg. 2020;24:191–2. - PubMed
    1. Lonowski S, Sachsman S, Patel N, Truong A, Holland V. Increasing evidence for omalizumab in the treatment of bullous pemphigoid. JAAD Case Rep. 2020;6:228–33. - PMC - PubMed
    1. Belmesk L, Muntyanu A, Cantin E, AlHalees Z, Jack CS, Le M, et al. Prominent role of type 2 immunity in skin diseases: Beyond atopic dermatitis. J Cutan Med Surg. 2022;26:33–49. - PubMed
    1. D’Aguanno K, Gabrielli S, Ouchene L, Muntyanu A, Ben-Shoshan M, Zhang X, et al. Omalizumab for the treatment of bullous pemphigoid: A systematic review of efficacy and safety. J Cutan Med Surg. 2022;26:404–13. - PubMed
    1. Kremer N, Snast I, Cohen ES, Hodak E, Mimouni D, Lapidoth M, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: A systematic review of the literature. Am J Clin Dermatol. 2019;20:209–16. - PubMed

Publication types